Related Experiment Videos
A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy
R Lo-Man1, S Bay, S Vichier-Guerre
1Unité de Biologie des Régulations Immunitaires, Institut Pasteur, 75724 Paris, France. rloman@pasteur.fr
Abstract:
Aberrant glycosylation of mucins leads to the exposure of cryptic carbohydrate antigens at the surface of carcinoma cells, which, therefore, represent potent targets for anticancer therapeutic vaccines. To date, the development of immunogens to stimulate immune response to such saccharidic antigens is based on carbohydrate conjugation to carrier proteins. However, these traditional protein conjugates are poorly defined in chemical composition and structure. As an alternative, we synthesized a multiple antigenic O-linked glycopeptide (MAG) carrying the carbohydrate Tn antigen associated with a CD4+ T-cell epitope (MAG:Tn-PV). This fully synthetic immunogen is highly defined in composition and carries a high saccharidic epitope ratio over the entire molecule. The MAG:Tn-PV was able to induce anti-Tn IgG antibodies that recognize human tumor cell lines. A therapeutic immunization protocol performed with this fully synthetic immunogen increased the survival of tumor-bearing mice. Thus, the accurately defined and versatile MAG system represents an efficient strategy to induce carbohydrate-specific antitumor immune responses but may also be applicable to the prevention of infectious diseases, if it is based on bacterial oligosaccharides.
Insights
Aberrant glycosylation exposes cancer targets. A novel synthetic glycopeptide immunogen (MAG:Tn-PV) effectively targets cancer cells, enhancing survival in mice and offering a versatile platform for therapeutic vaccines.
Area of Science:
- Oncology
- Immunology
- Carbohydrate Chemistry
Background:
- Aberrant glycosylation in carcinoma exposes carbohydrate antigens, making them targets for anticancer vaccines.
- Current immunogens (protein conjugates) have ill-defined chemical compositions and structures.
- There is a need for well-defined synthetic immunogens for cancer therapy.
Purpose of the Study:
- To develop a fully synthetic, well-defined immunogen for targeting cancer-associated carbohydrate antigens.
- To evaluate the efficacy of the synthetic immunogen in inducing antitumor immune responses.
- To assess the therapeutic potential of the synthetic immunogen in a preclinical cancer model.
Main Methods:
- Synthesis of a multiple antigenic glycopeptide (MAG) carrying the Tn antigen and a CD4+ T-cell epitope (MAG:Tn-PV).
- Characterization of the synthetic immunogen for defined composition and high saccharidic epitope ratio.
- Induction of antibodies and assessment of their reactivity against human tumor cell lines.
- Therapeutic immunization protocol in tumor-bearing mice to evaluate survival.
Main Results:
- The MAG:Tn-PV was successfully synthesized as a highly defined immunogen.
- MAG:Tn-PV induced anti-Tn IgG antibodies capable of recognizing human carcinoma cell lines.
- Therapeutic immunization with MAG:Tn-PV significantly increased the survival rate of tumor-bearing mice.
Conclusions:
- The multiple antigenic glycopeptide (MAG) system provides a well-defined and versatile strategy for inducing carbohydrate-specific antitumor immune responses.
- This synthetic approach offers advantages over traditional protein conjugates for developing therapeutic cancer vaccines.
- The MAG system holds potential for applications beyond cancer, including infectious disease prevention using bacterial oligosaccharides.